1036381-91-5

Basic information

• Product Name: Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate
• Synonyms: Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate
• CAS NO: 1036381-91-5
• Molecular Formula: C₁₃H₁₈N₂O₃
• Molecular Weight: 250.29362
• Mol File: 1036381-91-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate(1036381-91-5)
• EPA Substance Registry System: Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate(1036381-91-5)

Safety Data

• Hazardous Substances Data: 1036381-91-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate is used as a building block for the synthesis of potential pharmaceutical drugs. Its unique structure and properties contribute to the development of new drugs and medicinal compounds, enhancing their therapeutic potential and efficacy.
Used in Drug Synthesis:
In the pharmaceutical industry, Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate is used as a key intermediate in the synthesis of various drug molecules. Its presence in the molecular structure can impart specific biological activities and improve the pharmacokinetic properties of the resulting drugs.
Used in Medicinal Chemistry:
Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate is employed as a versatile compound in medicinal chemistry for the design and optimization of drug candidates. Its unique structural features allow for the exploration of novel chemical space and the identification of potential drug targets.
Used in Drug Discovery:
In the field of drug discovery, Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate is used as a starting material for the development of new chemical entities. Its complex structure and potential biological activity make it a promising candidate for the identification of novel therapeutic agents.
Used in Laboratory Settings:
Due to its complex structure and potential biological activity, Tert-butyl 2-oxo-1,2,7,8-tetrahydro-1,6-naphthyridine-6(5h)-carboxylate is used with caution in laboratory settings. Proper handling and safety measures are essential to ensure the safety of researchers and the integrity of experimental results.

Upstream product

• 601514-58-3 6-benzyl-5,6,7,8-tetrahydro-[1,6]-naphthyridin-2(1H)-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7341-96-0 2-propynamide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 116986-08-4 methyl 2-(bromomethyl)pyridine-3-carboxylate 
• 155058-02-9 7,8-Dihydro-1,6-Naphthyridine-5(6H)-one 
• 80957-68-2 5,6,7,8-tetrahydro-1,6-naphthyridine 
• 207691-65-4 N-tert-butoxycarbonyl-4-(tetrahydropyrrole-1-yl)-1,2,3,6-tetrahydropyridine 
• 65719-09-7 methyl 2-methylnicotinate 
• 1151665-15-4 2-chloro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 259809-45-5 tert-butyl 1-oxo-7,8-dihydro-5H-1-lambda-5-1,6-naphthyridine-6-carboxylate 
• 259809-44-4 7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 

Downstream Products

• 1149333-40-3 2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-carboxylic acid tert-butyl ester 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

BICYCLIC DERIVATIVES AS GABAA Α5 RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Inhibiting effect of trisubstituted pyrimidine derivative on protein kinase

The invention discloses a trisubstituted pyrimidine derivative with a structure shown as general formula (I), and pharmaceutically acceptable salt, ester or solvent compound thereof. The derivative isa protein kinase inhibitor, can be used individually or in combination with other drugs for cancer treatment, and has tremendous clinical application value. General formula (I) is shown as the specification.

SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS

The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof

Tetrahydroquinolinone and tetrahydronaphthyridone cannabinoid receptor ligand compounds and stereoisomers, mixtures of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, and isomorphic crystalline forms the